Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Allarity Therapeutics Inc's Business Segments
Allarity Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
License
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- License0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 0 | - |
Description of Allarity Therapeutics Inc
Allarity Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for personalized cancer treatment. The company specializes in identifying and advancing breakthrough drug candidates that can provide effective treatment options for patients with aggressive and difficult-to-treat forms of cancer.
Allarity utilizes its proprietary Drug Response Prediction (DRP) platform to identify potential therapeutic candidates. The DRP platform is an innovative approach that uses functional genomic profiling to match an individual patient's cancer with the most suitable drug treatment options. This personalized approach allows physicians to make more informed decisions regarding treatment and increases the probability of a positive response.
The DRP platform combines comprehensive genomic profiling, molecular biology, and bioinformatics to analyze and interpret a patient's tumor biology. This analysis helps to predict the patient's response to various drugs, enabling the selection of the most appropriate treatment option. Allarity aims to develop a broad portfolio of drug candidates that have been validated through the DRP platform and are ready for clinical trials.
The company's flagship drug candidate, called stenoparib (formerly known as 2X-121), is being developed as a potential treatment for ovarian cancer, breast cancer, and metastatic colorectal cancer. Stenoparib is a PARP inhibitor, which works by inhibiting a protein involved in DNA repair. By blocking this protein, stenoparib can prevent cancer cells from repairing damaged DNA, leading to their eventual death.
Allarity is also advancing other drug candidates through its pipeline, targeting different forms of cancer, including brain cancer, lung cancer, and melanoma. These drug candidates are being evaluated for their potential effectiveness in specific patient populations based on the DRP platform's predictions.
In addition to its drug development efforts, Allarity is actively collaborating with leading academic institutions, pharmaceutical companies, and medical centers to enhance its understanding of cancer biology and advance personalized cancer treatments. The company aims to leverage these collaborations to expedite the development and commercialization of its drug candidates.
Overall, Allarity Therapeutics Inc. is at the forefront of personalized cancer treatment, utilizing its innovative DRP platform to develop targeted therapies that can significantly improve patient outcomes. With a strong portfolio of drug candidates and strategic collaborations, the company is well-positioned to make a significant impact in the field of oncology.
Allarity utilizes its proprietary Drug Response Prediction (DRP) platform to identify potential therapeutic candidates. The DRP platform is an innovative approach that uses functional genomic profiling to match an individual patient's cancer with the most suitable drug treatment options. This personalized approach allows physicians to make more informed decisions regarding treatment and increases the probability of a positive response.
The DRP platform combines comprehensive genomic profiling, molecular biology, and bioinformatics to analyze and interpret a patient's tumor biology. This analysis helps to predict the patient's response to various drugs, enabling the selection of the most appropriate treatment option. Allarity aims to develop a broad portfolio of drug candidates that have been validated through the DRP platform and are ready for clinical trials.
The company's flagship drug candidate, called stenoparib (formerly known as 2X-121), is being developed as a potential treatment for ovarian cancer, breast cancer, and metastatic colorectal cancer. Stenoparib is a PARP inhibitor, which works by inhibiting a protein involved in DNA repair. By blocking this protein, stenoparib can prevent cancer cells from repairing damaged DNA, leading to their eventual death.
Allarity is also advancing other drug candidates through its pipeline, targeting different forms of cancer, including brain cancer, lung cancer, and melanoma. These drug candidates are being evaluated for their potential effectiveness in specific patient populations based on the DRP platform's predictions.
In addition to its drug development efforts, Allarity is actively collaborating with leading academic institutions, pharmaceutical companies, and medical centers to enhance its understanding of cancer biology and advance personalized cancer treatments. The company aims to leverage these collaborations to expedite the development and commercialization of its drug candidates.
Overall, Allarity Therapeutics Inc. is at the forefront of personalized cancer treatment, utilizing its innovative DRP platform to develop targeted therapies that can significantly improve patient outcomes. With a strong portfolio of drug candidates and strategic collaborations, the company is well-positioned to make a significant impact in the field of oncology.
Allarity Therapeutics Inc. is a biotechnology company that primarily focuses on the development of targeted cancer therapeutics. The company’s offerings can be segmented into various categories, which include its therapeutic products, proprietary technologies, and related services for enhancing cancer treatment options.
Segments
1. Therapeutics Development
- Allarity’s core segment focuses on developing and commercializing innovative cancer therapies. The companys approach revolves around identifying and targeting specific cancer cell mechanisms to ensure that treatments are more effective and have fewer side effects compared to traditional therapies.
2. Companion Diagnostics
- This segment is dedicated to the development and implementation of diagnostic tests that help determine which patients are most likely to benefit from specific treatments. By providing robust companion diagnostics, Allarity enhances the therapeutic efficacy of its products through personalized medicine.
3. Research & Development
- Allarity invests significant effort into R&D to expand its product pipeline. This involves preclinical and clinical trials to ensure that new therapies meet regulatory standards and demonstrate effectiveness in treating various cancer types.
Products
1. Candidate Drug Products
- Allarity is known for its candidate drugs that target specific pathways involved in cancer progression. These drugs are often in various stages of clinical trials.
- DRP® Technology: This proprietary technology is pivotal to Allaritys drug development process. The Drug Response Predictor (DRP®) platform is used to personalize cancer therapy by predicting how individual patients will respond to cancer drugs based on their unique tumor profile.
2. Clinical Stage Assets
- Allarity has developed several molecules with promising anti-cancer properties, which include small molecules, monoclonal antibodies, and other biologic therapeutics. These may target various types of cancer, including, but not limited to, breast, prostate, and lung cancers.
3. Combination Therapies
- The company also explores combinations of therapies to create synergistic effects that enhance the overall treatment outcome for cancer patients. This approach may involve the combination of its proprietary drugs with approved therapies to improve efficacy.
Services
1. Diagnostic Services
- Alongside its therapeutics, Allarity offers services related to companion diagnostics, helping healthcare providers identify the most effective treatment pathways for individual patients through advanced molecular profiling of tumors.
2. Clinical Trial Management
- Allarity may provide services related to the management and execution of clinical trials. This can involve coordinating various stakeholders, including investigators, patients, and regulatory bodies to ensure that trials are conducted efficiently and ethically.
3. Data Analytics and Bioinformatics
- The company likely leverages data analytics and bioinformatics to enhance its drug development processes. This can involve sophisticated data modeling to predict outcomes of clinical trials or determining patient selection criteria based on genetic and molecular characteristics.
4. Regulatory Consultancy
- Navigating the complex landscape of drug approval requires extensive regulatory knowledge. Allarity may provide consultancy services to other biotech firms regarding compliance with FDA regulations and preparing for New Drug Applications (NDAs) or Investigational New Drug (IND) applications.
Conclusion
Allarity Therapeutics Inc. operates at the intersection of biopharmaceutical innovation and precision medicine with a focus on cancer treatment. By leveraging advanced technologies like DRP® and developing personalized therapies, the company aims to make substantial contributions to the field of oncology. Through a multi-faceted approach encompassing drugs, diagnostics, and services, Allarity seeks to improve outcomes for cancer patients and enhance treatment personalization.
Segments
1. Therapeutics Development
- Allarity’s core segment focuses on developing and commercializing innovative cancer therapies. The companys approach revolves around identifying and targeting specific cancer cell mechanisms to ensure that treatments are more effective and have fewer side effects compared to traditional therapies.
2. Companion Diagnostics
- This segment is dedicated to the development and implementation of diagnostic tests that help determine which patients are most likely to benefit from specific treatments. By providing robust companion diagnostics, Allarity enhances the therapeutic efficacy of its products through personalized medicine.
3. Research & Development
- Allarity invests significant effort into R&D to expand its product pipeline. This involves preclinical and clinical trials to ensure that new therapies meet regulatory standards and demonstrate effectiveness in treating various cancer types.
Products
1. Candidate Drug Products
- Allarity is known for its candidate drugs that target specific pathways involved in cancer progression. These drugs are often in various stages of clinical trials.
- DRP® Technology: This proprietary technology is pivotal to Allaritys drug development process. The Drug Response Predictor (DRP®) platform is used to personalize cancer therapy by predicting how individual patients will respond to cancer drugs based on their unique tumor profile.
2. Clinical Stage Assets
- Allarity has developed several molecules with promising anti-cancer properties, which include small molecules, monoclonal antibodies, and other biologic therapeutics. These may target various types of cancer, including, but not limited to, breast, prostate, and lung cancers.
3. Combination Therapies
- The company also explores combinations of therapies to create synergistic effects that enhance the overall treatment outcome for cancer patients. This approach may involve the combination of its proprietary drugs with approved therapies to improve efficacy.
Services
1. Diagnostic Services
- Alongside its therapeutics, Allarity offers services related to companion diagnostics, helping healthcare providers identify the most effective treatment pathways for individual patients through advanced molecular profiling of tumors.
2. Clinical Trial Management
- Allarity may provide services related to the management and execution of clinical trials. This can involve coordinating various stakeholders, including investigators, patients, and regulatory bodies to ensure that trials are conducted efficiently and ethically.
3. Data Analytics and Bioinformatics
- The company likely leverages data analytics and bioinformatics to enhance its drug development processes. This can involve sophisticated data modeling to predict outcomes of clinical trials or determining patient selection criteria based on genetic and molecular characteristics.
4. Regulatory Consultancy
- Navigating the complex landscape of drug approval requires extensive regulatory knowledge. Allarity may provide consultancy services to other biotech firms regarding compliance with FDA regulations and preparing for New Drug Applications (NDAs) or Investigational New Drug (IND) applications.
Conclusion
Allarity Therapeutics Inc. operates at the intersection of biopharmaceutical innovation and precision medicine with a focus on cancer treatment. By leveraging advanced technologies like DRP® and developing personalized therapies, the company aims to make substantial contributions to the field of oncology. Through a multi-faceted approach encompassing drugs, diagnostics, and services, Allarity seeks to improve outcomes for cancer patients and enhance treatment personalization.